{"id":152,"date":"2025-01-23T10:00:00","date_gmt":"2025-01-23T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=152"},"modified":"2025-10-17T07:46:58","modified_gmt":"2025-10-17T07:46:58","slug":"china-bd-2025-lepu-biopharma-and-arrivent-enters-a-1-63-billion-usd-license-on-cdh17-adc-mrg007","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/152.html","title":{"rendered":"[China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007"},"content":{"rendered":"\n<p>Announced Date: 2025-01-22 (January 22, 2025)<\/p>\n\n\n\n<p>Licensor (Seller): Lepu Biopharma (China)<\/p>\n\n\n\n<p>Licensee (Buyer): ArriVent BioPharma (US)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Name: MRG007<\/p>\n\n\n\n<p>Asset Modality: ADC (antibody drug conjugate)&nbsp;<\/p>\n\n\n\n<p>Asset Target: CDH17<\/p>\n\n\n\n<p>Potential Indication: Gastrointestinal (\u201cGI\u201d) Cancers<\/p>\n\n\n\n<p>Current Stage: IND enabling studies<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: &nbsp;<\/p>\n\n\n\n<p>Lepu Biopharma has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Upfront payment and Near-term payment of $47 million,<\/p>\n\n\n\n<p>Milestone payments up to &nbsp;$1.16 billion.<\/p>\n\n\n\n<p>Tiered royalties on net sales outside of&nbsp;Greater China.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/en.lepubiopharma.com\/new\/210.html\">Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Lepu Biopharma, \u4e50\u666e\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-01-22 (January 22, 2025) Licensor (Seller): Lepu Biopharma (China) Licensee (Buyer): ArriVent BioPharma (US) &hellip; <a title=\"[China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/152.html\"><span class=\"screen-reader-text\">[China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-152","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=152"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/152\/revisions"}],"predecessor-version":[{"id":390,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/152\/revisions\/390"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}